Güler YAYLI, Fusun Zeynep AKÇAM, Onur KAYA

Investigation of the in vitro activities of various antibiotics against Brucella melitensis strains

To assess the antimicrobial susceptibility of Brucella melitensis strains in our region. Brucellosis is a common disease in Turkey. Moreover, difficulties are encountered in the treatment process, such as long-lasting therapy, relapses, and side effects of drugs. Hence, novel treatment approaches and the susceptibility of current antibiotics are vital. Materials and methods: Thirty-four Brucella spp. isolated from blood samples of patients with brucellosis were included. Minimal inhibitory concentrations for tetracycline, rifampicin, streptomycin, ciprofloxacin, doxycycline, ceftriaxone, and levofloxacin were detected by broth microdilution. Results: Tetracycline had the lowest and streptomycin the highest MIC50 and MIC90 values, respectively. A total of 5 strains were intermediate-susceptible and 1 strain was resistant to rifampicin. Conclusion: Doxycycline and tetracycline seem to be quite effective antibiotics against Brucella melitensis strains. Although streptomycin and rifampicin have high MIC levels against Brucella melitensis strains in our region, inconsistencies between in vitro susceptibility and in vivo activity should be considered.

Anahtar Kelimeler:

Key words: Brucella, MIC, susceptibility

Investigation of the in vitro activities of various antibiotics against Brucella melitensis strains

Keywords:

Key words: Brucella, MIC, susceptibility,

PDF

___

Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. Th e new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-9. 2. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010; 14: 469-78.
Young Brucella species. In: Mandell GL, Bennett JE, Dolin EJ. R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia (PA): Churchill Livingstone; 2010. p.2921-5. 4. Solera J. Update on brucellosis: therapeutic challenges. Int J Antimicrob Agents 2010; 36: S18-20.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI Document M100-S19. Wayne (PA): CLSI, 2009. 6. Food and Agriculture Organization, WHO. Joint FAO-WHO Expert Committee on Brucellosis, sixth report. In: World Health Organization Technical Report Series 740. Geneva: WHO; 1986. 7. Eşel D, Sümerkan B, Ayangil D, Telli M. Brucella melitensis suşlarının antibiyotik duyarlılıklarının belirlenmesinde agar dilüsyon ve E-test yöntemlerinin karşılaştırılması. Ankem Derg 2004; 18: 196-9.
Baykam N, Esener H, Ergönül Ö, Eren Ş, Çelikbas AK, Dokuzoğuz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
Turan H, Arslan H, Uncu H, Azap Ö, Şerefh anoğlu K. Tigesiklinin Brucella suşlarına in vitro etkinliğinin doksisiklin, siprofl oksasin ve rifampisinin etkinliği ile karşılaştırılması. İnfeksiyon Dergisi 2007; 21: 147-51.
Ayaşlıoğlu E, Kılıç S, Aydın K, Kılıç D, Kaygusuz S, Ağalar C. Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turk J Med Sci 2008; 38: 257-62.
Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5: 24.
Bosch J, Linares J, Lopez de Goicoechea MJ, Ariza J, Cisnal MC, Martin R. In-vitro activity of ciprofl oxacin, ceft riaxone and fi ve other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother 1986; 17: 459-61.
Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fl uoroquinolones against Brucella melitensis. Antimicrob Agents Chemother. 1999; 43: 194-5.
Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-300.
Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 2000; 40: 59-63.
Akova M, Uzun Ö, Akalin HE, Hayran M, Ünal S, Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofl oxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-4.
Agalar C, Usubutun S, Turkyilmaz R. Ciprofl oxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999; 18: 535-8.
Kocagöz S, Akova M, Altun B, Gür D, Hasçelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002; 8: 240-2.
Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925-7.